US/UK/Canada

Share

Quotes

The goal is to attract a licensing partner after completing phase I/II in order to continue the development. An alternative scenario is to find a partner before entering clinical studies, based on a precise development plan
Suzanne Kilany, CRD Aptahem
It is a very exciting result for any drug candidate to trigger a protein like Pentraxin-3 with such a broad spectrum of effects
Luiza Jedlina, CSO Aptahem
Aptahem is currently focusing on sepsis, but there is possibility for potentially expanding the indication. At present, no such decision has been made, but we are not ruling it out
Mikael Lindstam, CEO Aptahem
Pick a time period -
Tags ( Active)

Newsletter May 2026

World Sepsis Congress Highlights the Great Need for Apta-1Dear shareholders, In mid-April, the World Sepsis Congress convened leading experts from around the world, including WHO Director-General Dr. Tedros Adhanom Ghebreyesus. In his opening remarks, he highlighted the staggering scale of the problem : nearly 50 million people are affected by sepsis every year, and approximately 11 million die from it. He then added a sentence that captured the urgency of the issue with striking clarity: “Nobody should die while

Newsletter December 2025

Toward a New Trajectory: The CEO’s Reflections on Aptahem’s 2025A Year of Transformation, Deepening Capabilities, and Global Positioning Looking back at 2025, one thing is clear: this was the year when Aptahem truly began its transition from a promising Nordic biotech company into an organization with international presence, rigor, and ambition. We executed one of the most comprehensive advancement cycles in our history - scientifically, regulatorily, and strategically - with a single goal in mind: to bring Apta-1 to patients lacking effective treatment options. This progress unfolded

Aptahem’s webinar ”Strategic Direction and Planned US Listing” now available

Aptahem hosted a webinar where CEO Mikael Lindstam provided an overview of Aptahem’s strategic direction, ongoing preparations for a planned U.S. listing, and recent key regulatory developments.The webinar is available via the link below: https://gumlet.tv/watch/6902846960d267cdc081c34f/ For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99Epost: ml@aptahem.com About Aptahem Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a

Aptahem Announces English-Language Webinar on Strategic Direction and Planned U.S. Listing

Aptahem AB (publ) (“Aptahem” or the “Company”), a clinical-stage biotech company listed on the Spotlight Stock Market that develops RNA-based treatments for acute thrombo-inflammatory conditions, today announces that it will host an English-language investor webinar on Wednesday, October 29, 2025, at 3:00 p.m. CEST.The purpose of the webinar is to provide an overview of Aptahem’s strategic direction, ongoing preparations for a planned U.S. listing, and recent key regulatory developments. The English-language event follows the Company’s Swedish webinar held on September 22 and is intended to

Newsletter October 2025

From Global Statistics to Personal Stories by Madonna: Why Our Work at Aptahem MattersDear shareholders and stakeholders! Last week, the World Health Organization published a new report on the spread of drug resistance. While this does not directly affect Aptahem in the short term, I believe it is relevant for you as shareholders to understand some of the underlying drivers behind a megatrend that, in my view, will continue to increase the need for new and better treatments for sepsis — a role we hope Apta-1 will fulfill. In addition, there have recently been a few notable cases of

Aptahem moves forward with focus on U.S. listing strategy, regulatory progress, and partner engagement following outcome of rights issue

Aptahem AB (publ) (“Aptahem” or the “Company”), a clinical-stage biotech company listed on the Spotlight Stock Market that develops RNA-based treatments for acute thrombo-inflammatory conditions, today announces that, following the preliminary outcome of its rights issue, the Company will continue to pursue its strategic decision to move toward a U.S. listing, with a clear focus on operational efficiency.As communicated on 26 August 2025, Aptahem has initiated a process to become listed on a U.S. stock exchange, with the goal of achieving a market valuation that better reflects the Company’

Aptahem receives Notice of Allowance in China for patent family 2

Aptahem AB (publ) announces today that the company has received a Notice of Allowance in China of the patent application no 2018800643106 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties.The notice of allowance is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent. When issued, the patent will be valid until, and including, 2038. CEO Mikael Lindstam comments: ”The fact that we have now received notification that

Aptahem Outlines Ongoing Preparations for Planned U.S. Listing and Announces Webinar Invitation

Aptahem AB (publ) (“Aptahem” or the “Company”), a clinical-stage biotech company listed on the Spotlight Stock Market that develops RNA-based treatments for acute thrombo-inflammatory conditions, today provides an update on the Company’s preparations for a planned U.S. listing and announces an upcoming webinar on Monday, September 22, to which all interested parties are invited (see details below).The initiative to pursue a U.S. listing is part of the strategic direction announced on August 26, aimed at achieving a market valuation that more accurately reflects the Company’s scientific

Aptahem enters strategic collaboration agreement with e-Projection to more efficiently achieve partnership in Japan

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the company enters into a strategic collaboration agreement with the Japanese company e-Projection to accelerate potential partnering opportunities with pharma and biotech companies in Japan. E-Projection acts in the area of business development with focus on the Japanese market and has the advantage of knowledge in language, culture, networks and experience which has been essential for Aptahem to enter into an agreement. The agreement

Aptahem comments on interesting data after finalised phase 1 study

Aptahem AB (publ), a biotechnology company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, today announced that the completed double-blind randomised placebo-controlled phase 1 study in healthy volunteers also showed indications of drug efficacy.1. Aptahem has summarised and concluded all additional analyses taking into account the recently completed phase 1 study. 2. At dosing, interesting immunological marker responses were noted in the subjects, prompting further analyses and evaluation of safety and mechanism of action. 3. The analyses

Aptahem’s scientific manuscript in collaboration with the research group at UHN in Toronto has been approved for publication in the journal Cells

The ground-breaking results from the studies performed with the drug candidate Apta-1, in collaboration with the research group at University Health Network (UHN) in Toronto, in various serious disease models have now lead to a first approval for publication.The collaboration with the group in Toronto, lead by Professor Mingyao Liu, and from Aptahem Dr Luiza Jedlina, has been ongoing for some time and included several study steps in a SARS (Severe Acute Respiratory Syndrome) Corona lung model, which Aptahem previously has reported. The SARS Corona virus which has been used in the studies is

Aptahem reports promising outcome from the additional analyses on the mechanism on lead candidate Apta-1 in the FIH study

Aptahem AB (publ) announces today that the results from the additional analyses performed in cohorts 1 to 4 in the First in Human (FIH) study, have contributed to the clarification of Apta-1's impact on clinical biomarkers. Next step is to apply for approval to continue the study.Aptahem has now finalized the analyses recommended by the Data Review Committee. The data showed promising results regarding the effect of Apta-1 on clinical biomarkers. Aptahem will swiftly compile the data and aim to submit to the Ethics Committee and Competent Authority as soon as possible after the data review

Aptahem attends the BioStock Investor Meeting on 20 September 2023

Aptahem’s CEO Mikael Lindstam is presenting the company and gives an update on the ongoing activities. The presentation, which is held in English, can be followed at the physical event in Stockholm on 20 September at 15.00 CET.More information about the event and link to registration page is available on the BioStock website . For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA) is a

BioStock article: Aptahem's CEO comments on Q2 and looks ahead

For Aptahem, the second quarter continued to focus on the clinical development of drug candidate Apta-1 against sepsis. However, the company recently put the clinical phase Ia study on hold after making, what it called, interesting findings. BioStock talked to CEO Mikael Lindstam to get an update.Read the interview with Aptahem's CEO Mikael Lindstam at Aptahem’s website . For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem

BioStock-article: Aptahem comments on the paused phase I study

Aptahem develops the drug candidate Apta-1 as an acute treatment of sepsis. Recently, the company announced that the ongoing phase Ia study had been temporarily paused after observing interesting data. To learn more about the significance of this data, BioStock contacted Aptahem’s CEO Mikael Lindstam.Read the full interview with Mikael Lindstam at biostock.se: https://www.biostock.se/en/2023/07/aptahem-comments-on-the-paused-phase-i-study/ For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA)

In Aptahem’s FIH study further analytic studies will be performed

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that in the double-blinded randomized placebo controlled first-in-human (FIH) clinical trial further analytic studies on the mechanism of Apta-1 are recommended which will result in a temporary hold of the study.During the course of the study, additional analyses have been performed, which indicated interesting findings. After reviewing the data, the Data Review Committee concluded that further assays would be recommended. Aptahem are using this

BioStock article: Aptahem gives update on operations and rights issue

Aptahem is making strides in the field of sepsis treatment with its drug candidate Apta-1. Recently, the company announced the completion of a fourth cohort in the ongoing phase I clinical study. Aptahem has also attended key partnering conferences to showcase its potential sepsis treatment. To learn more about this, and the share issue of 28 MSEK between 14 June – 28 June 2023, BioStock talked to CEO Mikael Lindstam.Read the interview with Aptahem's CEO Mikael Lindstam at biostock.se: https://www.biostock.se/en/2023/06/aptahem-gives-update-on-operations-and-rights-issue/ For further

Aptahem’s presentation at the BioStock Life Science Summit now available

Aptahem’s CEO Mikael Lindstam presented the company and gave an update on the ongoing activities at the BioStock Life Science Summit on 31 May 2023.The presentation, which is held in English, is now available at the company’s website: https://aptahem.com/videos/video-category/presentations/ For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which

Fourth cohort completed in Aptahem’s FIH study

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today the completion of an additional cohort in the ongoing double-blinded randomized placebo controlled clinical First in Human (FIH) study.During the course of the study, there have been signs of interesting effects on clinical markers. Therefore, before starting the next cohort, extended analyses will be performed to gain a greater understanding of Apta-1’s clinical significance. These analyses will form an important basis for the further clinical

Aptahem attends the BioStock Life Science Summit on 31 May 2023

Aptahem’s CEO Mikael Lindstam is presenting the company and gives an update on the ongoing activities. The presentation, which is held in English, can be followed online on 31 May at 12.50 CET.More information about the event is available on the BioStock Life Science Summit website: https://www.biostock.se/en/biostock-life-science-summit-may-2023/ For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for

BioStock article: Aptahem on the need for more effective sepsis treatments

Biotechnology company Aptahem is developing Apta-1, a drug candidate whose purpose is to reduce the high mortality and severe tissue damage that can occur in sepsis. BioStock contacted Luiza Jedlina, Chief Scientific Officer and co-founder of Aptahem, to talk about the need for better treatment options than antibiotics.Read the full interview with Luiza Jedlina at biostock.se: https://www.biostock.se/en/2023/04/aptahem-on-the-need-for-more-effective-sepsis-treatments/ For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com

Third cohort completed in Aptahem’s FIH study

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the third cohort of healthy volunteers (HV) has been dosed and completed in the clinical First in Human (FIH) study.After the follow-up visits of this third cohort, Apta-1 continues to be safe and well tolerated. The study will continue according to plan with dosing HV in the fourth cohort later this month. For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem

Second cohort in Aptahem’s FIH study performed and approved by the ethics committee

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the second dose cohort in the clinical First in Human (FIH) study in healthy volunteers has been performed and approved by the Dutch ethics committee.The purpose of the study is to evaluate safety and tolerability of Apta-1 in various doses. As previously communicated, the second dose cohort was initiated in early January 2023 and has now been finalized and approved by the authority. Apta-1 seems to continue to be safe and well tolerated

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe